Click here to return to ‘trade topics’

INTELLECTUAL PROPERTY: WHO-WIPO-WTO BOOK

Promoting Access to Medical Technologies and Innovation:

Intersections between public health, intellectual property and trade

 

Bibliography

Abbott, F.M. and Van Puymbroeck, R.V. (2005), Compulsory Licensing for Public Health: A Guide and Model Documents for Implementation of the Doha Declaration Paragraph 6 Decision, Washington, DC, World Bank.

Abbott, F.M. and Correa, C.M. (2007), World Trade Organization Accession Agreements: Intellectual Property Issues, Geneva, QUNO.

Abbott, F.M. and Reichman, J.H. (2007), “The Doha Round’s Public

Health Legacy: Strategies for the Production and Diffusion of

Patented Medicines under the Amended TRIPS Provisions”, Journal

of International Economic Law 10(4): 921–87.

Adlung, R. (2010), “Trade in Healthcare and Health Insurance

Services: WTO/GATS as a Supporting Actor (?)”, Intereconomics

45(4): 227–38.

Anderson, R.D., Kovacic, W.E. and Müller, A.C. (2011), “Ensuring

Integrity and Competition in Public Procurement Markets:

A Dual Challenge for Good Governance”, in Arrowsmith, S. and

Anderson, R.D. (eds.), The WTO Regime on Government Procurement:

Challenge and Reform, Cambridge, Cambridge University Press,

pp. 681–718.

Attaran, A. (2004), “How Do Patents and Economic Policies Affect

Access to Essential Medicines in Developing Countries”, Health

Affairs 23(3): 155–66.

Ball, D. (2011), “Working Paper 3: The Regulation of Mark-ups in

the Pharmaceutical Supply Chain”, Review Series on Pharmaceutical

Pricing Policies and Interventions.

Ballance, R. Pogany, J. and Forstner, H. (1992), The World’s Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy, Aldershot, Edward Elgar.

Ben-Ayre, E. et al. (2012), “Integrative Oncology in the Middle East: From Traditional Herbal Knowledge to Contemporary Cancer Care”, Annals of Oncology 23(1): 211–21.

Berndt, E., Blalock, N. and Cockburn, I. (2011), “Diffusion of New Drugs in the Post-TRIPS Era”, International Journal of the Economics of Business 18(2): 203–24.

Beyer, P. (2012), “Developing Socially Responsible Intellectual Property Licensing Policies: Non-Exclusive Licensing Initiatives in the Pharmaceutical Sector”, in de Werra, J. (ed.), La propriété intellectuelle dans l’industrie pharmaceutique: Intellectual Property in the Pharmaceutical Industry, Zürich, Schulthess Verlag.

BIO Ventures (2010), The Diagnostics Innovation Map: Medical Diagnostics for the Unmet Needs of the Developing World, Washington, DC, BIO Ventures for Global Health.

Blouin, C., Drager, N. and Smith, R., (eds.) (2006), International Trade in Health Services and the GATS: Current Issues and Debates, Washington, DC, World Bank.

Bregonje, M. (2005), “Patents: A Unique Source for Scientific Technical Information in Chemistry Related Industry?”, World Patent Information 27(4): 309–15.

Cameron, A. et al. (2009), “Medicine Prices, Availability, and Affordability in 36 Developing and Middle-Income Countries: A Secondary Analysis”, The Lancet 373(9659): 240–49.

Cameron, A. and Laing, R. (2010), “Cost Savings of Switching Private Sector Consumptions from Originator Brand Medicines to Generic Equivalents”, World Health Report Background Paper No. 35.

Cameron A. et al. (2011), “Differences in the Availability of Medicines for Chronic and Acute Conditions in the Public and Private Sectors of Developing Countries”, Bulletin of the World Health Organization 89(6): 412–21.

Chaudhuri, S., Goldberg, P.K. and Jia, P. (2006), “Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India”, American Economic Review 96(5): 1477–1514.

CIOMS (2002), International Ethical Guidelines for Biomedical Research Involving Human Subjects, Geneva, Council for International Organizations of Medical Sciences.

Clift, C. (2010), “Combating Counterfeit, Falsified and Substandard Medicines: Defining the Way Forward?”, Chatham House Briefing Paper.

Cohen, W.M., Nelson, R.R. and Walsh, J.P. (2000), “Protecting Their Intellectual Assets: Appropriability Conditions and Why US Manufacturing Firms Patent (or Not)”, NBER Working Paper 7552.

Comanor, W.S. (1986), “The Political Economy of the Pharmaceutical Industry”, Journal of Economic Literature 24(3): 1178–1217.

Competition Bureau (2000), Intellectual Property Enforcement Guidelines, Ottawa, Competition Bureau.

Commission on Health Research for Development (1990), Health Research: Essential Link to Equity in Development, New York, Oxford University Press.

Cornish, W. (2003), Intellectual Property: Patents, Copyright, Trade Marks and Allied Rights, 4th Edition, United Kingdom, Sweet and Maxwell.

Correa, C.E. (2009), “Case 2. The SARS Case: IP Fragmentation and Patent Pools”, in Van Overwalle, G. (ed.), Gene Patents and Collaborative Licensing Models, Cambridge, Cambridge University Press, pp. 33–41.

Correa, C.M. (2004), Implementation of the WTO General Council Decision on Paragraph 6 of the DOHA Declaration on the Trips Agreement and Public Health, Health Economics and Drugs Series No. 016, Geneva, WHO.

Creese, A., (2011), “Working Paper 5: Sales Taxes on Medicines”, Review Series on Pharmaceutical Pricing Policies and Interventions.

Danzon, P.M., Mulcahy, A.W. and Towse, A.K. (2011), “Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement”, NBER Working Paper 17174.

DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003), “The Price of Innovation: New Estimates of Drug Development Costs”, Journal of Health Economics 22(2): 151–85.

DiMasi, J.A. and Grabowski, H.G. (2007), “The Cost of Biopharmaceutical R&D: Is Biotech Different?” Managerial and Decision Economics 28: 469–79.

EDCTP (2011), 2011 Annual Report, The Hague, European Developing Countries Clinical Trials Partnerships.

EMA (2012), Access to Clinical-Trial Data and Transparency: Workshop Report, European Medicines Agency.

Espin, J., Rovira, J., Olry de Labry, A., (2011), “Working Paper 1: External Reference Pricing”, Review Series on Pharmaceutical Pricing Policies and Interventions.

European Commission (2003), Vaccines Research Relief: Introduction of a New Scheme and Modification of State Aid N 802/99, European Commission C(2003) 1398.

European Commission (2009), Pharmaceutical Sector Inquiry: Final Report, European Commission.

European Commission (2010), Reports on EU Customs Enforcement of Intellectual Property Rights: Results at the EU Border – 2010, Luxembourg, European Commission.

European Commission (2012), “Medical Devices: European Commission Calls for Immediate Actions – Tighten Controls, Increase Surveillance, Restore Confidence”, Press release IP/12/119 of 9 February 2012.

Fink, C. (2011), “Intellectual Property Rights”, in Chauffour, J.P. and Maur, J.C. (eds.), Preferential Trade Agreement Policies for Development: A Handbook, Washington, DC, World Bank, pp. 387–406.

Frost, L.J., and Reich, M.R. (2010), “How Do Good Health Technologies Get to Poor People in Poor Countries”, Massachusetts, Harvard Center for Population and Development Studies.

Ganslandt, M. and Maskus, K.E. (2004), “Parallel Imports and the Pricing of Pharmaceutical Products: Evidence from the European Union,” Journal of Health Economics 23(5): 1035–57.

Garrido, M.V. et al. (2008), Health Technology Assessment and Health Policy-Making in Europe: Current Status, Challenges and Potential, WHO-Europe/European Observatory on Health Systems and Policies.

GE Healthcare (2011), “Market-Relevant Design: Making ECGs Available Across India”, Newsroom, 30 September 2011.

GHTF (2005), Information Document Concerning the Definition of the Term “Medical Device”, Global Harmonization Task Force document GHTF/SG1/N29R16:2005.

Global Fund (2010a), Procurement and Supply Management (PSM) Plan: Guide to Writing PSM Plans.

Global Fund (2010b), Procurement Support Services: Voluntary Pooled Procurement.

Government of India (2012), Guidelines on Similar Biologics: Regulatory Authorization Requirements for Marketing Authorization in India, New Delhi, Government of India.

Grabowski, H.G. and Kyle, M. (2007), “Generic Competition and Market Exclusivity Periods in Pharmaceuticals”, Managerial and Decision Economics 28(4–5): 491–502.

Grabowski, H.G., Ridley, D.B. and Moe, J.L. (2008), “Priority Review Vouchers to Encourage Innovation for Neglected Diseases”, North Carolina, Duke University.

Grace, C. (2010), “Product Development Partnerships (PDPs): Lessons from PDPs Established to Develop New Health Technologies for Neglected Diseases”, Department for International Development, United Kingdom.

Greene, J. (2010), “When Did Medicines Become Essential?”, Bulletin of the World Health Organization 88(7): 483.

Gottret, P. and Schieber, G. (2006), Health Financing Revisited: A Practitioner’s Guide, Washington, DC, World Bank.

Hawkins, L. (2011), “Working Paper 4: Competition Policy”, Review Series on Pharmaceutical Pricing Policies and Interventions.

Helble, M. (2012), “More Trade for Better Health? International Trade and Tariffs on Health Products”, WTO Staff Working Paper ERSD-2012–17.

Hendriks, J. et al. (2011), “An International Technology Platform for Influenza Vaccines,” Vaccine, 29(Suppl. 1): A8–A11.

’t Hoen, E.F.M. (2009), The Global Politics of Pharmaceutical Monopoly Power, Diemen, AMB Publishers.

Hogerzeil, H.V. et al. (2006), “Is Access to Essential Medicines as Part of the Fulfilment of the Right to Health Enforceable Through the Courts?”, Lancet 368: 305–11.

Hogerzeil, H.V. and Mirza, Z. (2011), The World Medicines Situation: Access to Essential Medicines as Part of the Right to Health, Geneva, WHO.

Holloway, K. and van Dijk, L. (2011), The World Medicines Situation: Rational Use of Medicines, Geneva, WHO.

ICTSD/UNCTAD/WHO (2007), Draft Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health Perspective, Geneva.

IFPMA (2011), The Pharmaceutical Industry and Global Health: Facts and Figures, Geneva, IFPMA.

IFPMA (2013), Pharmaceutical R&D Projects to Discover Cures for Patients with Neglected Conditions: 2012 Status Report on Pharmaceutical R&D to Address Diseases that Disproportionately Affect People in Low- and Middle-Income Countries, Geneva, IFPMA.

IPO (2011), Patent Thickets: An Overview, Newport, Intellectual Property Office.

Immelt, J.R., Govindarajan, V. and Trimble, C. (2009), “How GE is Disrupting Itself,” Harvard Business Review, October.

Institute of Medicine (2012), “Ensuring Safe Foods and Medical Products Through Stronger Regulatory Systems Abroad”, Report Brief, National Academy of Sciences.

Kanavos, P. et al. (2010), “The Impact of Health Technology Assessments: An International Comparison 2010”, Euro Observer 12(4): 1–7.

Kaplan, W. and Laing, R. (2005), “Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines”, HNP Discussion Paper, Washington, DC, World Bank.

Ker, U. (2012), “Advance Market Commitment: Saving Lives Through Vaccine Delivery – UPDATE,” Case Studies for Global Health.

Khor, M. (2007), “Patents, Compulsory Licences and Access to Medicines: Some Recent Experiences”, TWN Intellectual Property Series 10.

King, D.R. and Kanavos, P. (2002), “Encouraging the Use of Generic Medicines: Implications for Transition Economies”, Croatian Medical Journal 43(4): 462–69.

Krasovec, K. and Connor, C. (1998), Using Tax Relief to Support Public Health Goals, Partners for Health Reformplus.

Krattiger, A. (2007a), “The Use of Nonassertion Covenants: A Tool to Facilitate Humanitarian Licensing, Manage Liability, and Foster Global Access”, in Krattiger, A. et al. (eds.), Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices, Oxford, MIHR and Davis, PIPRA, pp. 739–45.

Krattiger, A. et al. (eds.), (2007b) Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices, Oxford, MIHR and Davis, PIPRA, pp. 1317–27.

LaMattina, J.L. (2011), “The Impact of Mergers on Pharmaceutical R&D”, Nature Reviews Drug Discovery 10: 559–60.

Lanjouw, J.O. (2005), “Patents, Price Control, and Access to New Drugs: How Policy Affects Global Market Entry”, NBER Working Paper No. 11321.

Levin, R. et al. (1987), “Appropriating the Returns from Industrial Research and Development”, Brookings Papers on Economic Activity

3: 783–831.

Levison, L. and Laing, R. (2003), “The Hidden Costs of Essential

Medicines”, Essential Drugs Monitor 033.

Lichtenberg, F. (2012), “Pharmaceutical Innovation and Longevity

Growth in 30 Developing and High-Income Countries, 2000–2009”,

NBER Working Paper No. 18235.

Liu, L. et al. (2012), “Global, Regional, and National Causes of Child

Mortality: An Updated Systematic Analysis for 2010 with Time

Trends since 2000”, The Lancet 379(9832): 2151–61.

Light, D.W. and Warburton, R. (2011), “Demythologizing the High

Costs of Pharmaceutical Research”, BioSocieties 6: 34–50.

Love, J. (2003), “Evidence Regarding Research and Development

Investments in Innovative and Non Innovative Medicines”, Consumer

Project on Technology.

 

Mackey, T.K. and Liang, B.A. (2012), “Patent and Exclusivity Status of Essential Medicines for Non-Communicable Disease”, PLoS ONE 7(11): e51022.

Mansfield, E. (1986), “Patents and Innovation: An Empirical Study”, Management Science 32(2): 173–81.

Masum, H. and Harris, R. (2011), Open Source for Neglected Disease: Magic Bullet or Mirage?, Washington, DC, Results for Development Institute.

Mathers, C.D. et al. (2006), “The Burden of Disease and Mortality by Conditions: Data, Methods and Results for 2001”, in Lopez, A.D. et al. (eds.), Global Burden of Disease and Risk Factors, New York, Oxford University Press, pp. 45–240.

Mathers, C.D. and Loncar, D. (2006), “Projections of Global Mortality and Burden of Disease from 2002 to 2030”, PLoS Medicine 3(11): e442.

Matthijs, G. and Van Ommen, G.J. (2009) “Gene Patents: From Discovery to Invention. A Geneticist’s View”, in Van Overwalle, G. (ed.), Gene Patents and Collaborative Licensing Models, Cambridge, Cambridge University Press, pp. 311–30.

Maurer, S. (2007), “Open Source Drug Discovery: Finding a Niche (or Maybe Several)”, UMKC Law Review 75: 1–31.

Mendis, S., et al. (2007), “The Availability and Affordability of Selected Essential Medicines for Chronic Diseases in Six Low- and Middle-Income Countries”, Bulletin of the World Health Organization 85(4): 279–87.

Milstien, J.B., Batson, A. and Wertheimer, A.I. (2005), “Vaccines and Drugs: Characteristics of Their Use to Meet Public Health Goals”, HNP Discussion Paper, Washington, DC, World Bank.

Ministry of Health and Social Welfare (2008), Mapping of Partners and Financial Flows in the Medicines Supply System in Tanzania, Dar es Salaam, Ministry of Health and Social Welfare.

Mirza, Z. (2008), “Thirty Years of Essential Medicines in Primary Health Care”, East Mediterranean Health Journal 14 (Suppl): S74–S81.

MSH (2012), Managing Access to Medicines and Health Technologies, Arlington, Management Sciences for Health.

Mohiuddin, M. and Imtiazuddin, O. (2007), “Socially Responsible Licensing: Model Partnerships for Underserved Markets”, Acumen Fund Concepts.

Morgan, S. et al. (2011), “The Cost of Drug Development: A Systematic Review”, Health Policy 100(1): 4–17.

Moran, M. et al. (2005), The New Landscape of Neglected Disease Drug Development, The London School of Economics and Political Sciences.

Moran, M. et al. (2012), Neglected Disease Research And Development: A Five Year Review, G-Finder Report 2012, London, Policy Cures.

Müller, A.C. and Pelletier, P. (forthcoming), “Competition Policy and Government Procurement, Two Missing Links in the Debate on Public Health”, WTO Staff Working Paper.

Munos, B. (2009), “Lessons from 60 Years of Pharmaceutical Innovation,” Nature Reviews Drug Discovery 8: 959–68.

Murray, C.J.L. and Lopez, A.D. (eds.) (1996), The Global Burden of Disease, Cambridge, Harvard School of Public Health.

NCD Alliance (2011), “Access to Essential Medicines and Technologies for NCDs”, NCD Alliance Briefing Paper.

Newman, D.J. et al. (2008), “Medicines from Nature”, in Chivian, E. and Bernstein, A. (eds.) Sustaining Life: How Human Health Depends on Biodiversity, Oxford, Oxford University Press.

Niëns, L. et al. (2010), “Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World”, PLoS Medicine 7(8): e1000333.

NIH (2001), Glossary of Terms for Human Subjects Protection and Inclusion Issues, National Institute of Health.

Noor, W. (2009), “Placing Value on FDA’s Priority Review Vouchers”, IN VIVO 27(8): 1–8.

Nunn, A. et al. (2007), “Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment”, PLoS Medicine 4(11): e305.

Nwaka, S. et al. (2010), “Developing ANDI: A Novel Approach to Health Product R&D in Africa,” PLoS Medicine 7(6): e1000293.

Obrist, B. et al. (2007), “Access to Health Care in Contexts of Livelihood Insecurity: A Framework for Analysis and Action”, PLoS Medicine 4(10): e308.

OECD (2003), Transparency in Government Procurements: The Benefits of Efficient Governance and Orientations for Achieving It, Paris, OECD.

OECD (2008), Pharmaceutical Pricing Policies in a Global Market, Paris, OECD.

OECD (2011), OECD Science, Technology and Industry Scoreboard 2011: Innovation and Growth in Knowledge Economies, Paris, OECD.

OECS (2001), Pharmaceutical Procurement Service Annual Report 2001, Saint Lucia, Organisation of Eastern Caribbean States.

Office of Technology Assessment (1993), Pharmaceutical R&D: Costs, Risks and Rewards, Washington, DC, US Congress.

Olcay, M. and Laing, R. (2005), “Pharmaceutical Tariffs: What is Their Effect on Prices, Protection of Local Industry and Revenue Generation?”, Study prepared for the Commission on Intellectual Property Rights, Innovation and Public Health, WHO.

Olson, S. and Berger, A. (2011), Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Drug Development, National Academies Press.

Ombaka, E., (2009), “Current Status of Medicines Procurement”, American Journal of Health-System Pharmacy 66(Suppl 3): S20–S28.

Oxfam/MSF (2010), Giving Developing Countries the Best Shot: An Overview of Vaccine Access and R&D, Geneva, MSF.

Pateriya, S. et al. (2011), “Regulatory Aspects of Pharmaceuticals’ Exports in Gulf Cooperation Council Countries”, Journal of Young Pharmacists 3(2): 155–62.

Perehudoff, S.K. (2008), Health, Essential Medicines, Human Rights and National Constitutions, Geneva, WHO.

PhRMA (2007), Drug Discovery and Development: Understanding the R&D Process, Washington, DC, PhRMA.

Pray, L. (2008), “Personalized Medicine: Hope or Hype?,” Nature Education 1(1).

PwC (2008), Pharma 2020: Virtual R&D – Which Path Will You Take?, PricewaterhouseCoopers.

PwC (2012), Pharma 2020: From Vision to Decision, PricewaterhouseCoopers.

Rägo, L. and Santoso, B. (2008), “Drug Regulations: History, Present and Future”, in van Boxtel, C.J., Santoso, B. and Edwards, I.R. (eds.), Drug Benefits and Risks: International Textbook of Clinical Pharmacology, Amsterdam, IOS Press, pp. 65–78.

Reuters (2012), “EU Agency Lifts Lid on Drug Data Secrets”, 16 July 2012.

Ridley, D., Grabowski, H.G. and Moe, J.L. (2006), “Developing Drugs for Developing Countries”, Health Affairs 25(2): 313–24.

Rietveld, H. (2008), “A New Class of Malaria Drugs: The Coartem Breakthrough from Novartis and its Chinese Partners”, Workshop on Access and Benefit Sharing, Bonn, 26 May 2008.

Robertson, J. et al. (2009), “What Essential Medicines for Children are on the Shelf?”, Bulletin of the World Health Organization 87(3): 231–7.

Roger, S.D. and Goldsmith, D. (2008), “Biosimilars: It’s Not as Simple as Cost Alone”, Journal of Clinical Pharmacy and Therapeutics 33(5): 459–64.

Røttingen, J.-A. et al. (2012), “Securing the Public Good of Health Research and Development for Developing Countries”, Bulletin of the World Health Organization 90(5): 398–400.

Saberwal, G. (2010), “Bio-Business in Brief: The Debate over Biosimilars”, Current Science 98(12): 1575–78.

El Said, M.K. (2010), Public Health Related Trips-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators and Implementers in the WHO Eastern Mediterranean Region, Geneva, WHO/ICTSD.

Scheib, J. and Witherell, B. (2011), “The Basics of Drug and Medical Device Naming”, INTA Bulletin 66(15).

Scherer, F.M. (2001), “The Link Between Gross Profitability and Pharmaceutical R&D Spending”, Health Affairs 20(5): 216–20.

Scherer, F.M. and Watal, J. (2002), “Post-TRIPS Options for Access to Patented Medicines in Developing Nations”, Journal of International Economic Law 5(4): 913–39.

Shapiro, C. (2000), “Navigating the Patent Thicket: Cross Licences, Patent Pools and Standard Setting”, in Jaffe, A.B., Lerner, J. and Stern, S. (eds.), Innovation Policy and the Economy, Cambridge, MIT Press, pp. 119–50.

Simon, J. et al. (2005), “Managing Severe Acute Respiratory Syndrome (SARS) Intellectual Property Rights: The Possible Role of Patent Pooling”, Bulletin of the World Health Organization 83(9): 707–10.

Stevens, A.J. et al. (2011), “The Role of Public-Sector Research in the Discovery of Drugs and Vaccines”, New England Journal of Medicine 364(6): 535–41.

Taubman, A. (2010), “A Typology of Intellectual Property Management for Public Health, Innovation and Access: Design Considerations for Policymakers”, Open AIDS Journal 4: 4–24.

Taylor, C.T. and Silberston, Z.A. (1973), The Economic Impact of the Patent System: A Study of the British Experience, Cambridge, Cambridge Press University.

Temin, P. (1979), “Technology, Regulation, and Market Structure in the Modern Pharmaceutical Industry”, The Bell Journal of Economics 10(2): 429–46.

Tempest, B. (2011), “The Structural Changes in the Global Pharmaceutical Marketplace and Their Possible Implications for Intellectual Property”, ICTSD Policy Brief No. 10.

UNAIDS (2012), Global Fact Sheet: World Aids Day 2012, Geneva, UNAIDS.

UNAIDS/WHO/UNDP (2011), “Using TRIPS Flexibilities to Improve Access to HIV Treatment”, Policy Brief.

UNICEF (2012), Levels and Trends in Child Mortality Report 2012: Estimates Developed by the UN Inter-agency Group for Child Mortality Estimation, New York, UNICEF.

UNITAID (2009), “UNITAID and the Clinton HIV/AIDS Initiative Announce New Price Reductions for Key Drugs”, Geneva, WHO.

UNITAID (2011), HIV/AIDS: Scaling Treatment Up, Pushing Prices Down, Geneva, UNITAID.

United Nations (2011a), Political Declaration on HIV/AIDS: Intensifying Our Efforts to Eliminate HIV/AIDS, MDG Gap Task Force Report 2011, New York, UN General Assembly.

United Nations (2011b), Millennium Development Goal 8. The Global Partnership for Development: Time to Deliver, New York, United Nations.

United Nations (2012), The Millennium Development Goals Report 2012, New York, United Nations.

USCBO (2006), Research and Development in the Pharmaceutical Industry, Congress of the United States, Congressional Budget Office.

US Department of Justice/Federal Trade Commission (1995), Antitrust Guidelines for the Licensing of Intellectual Property.

Uzuner, H. et al. (2012), “Traditional Chinese Medicine Research in the Post-Genomic Era: Good Practice, Priorities, Challenges and Opportunities”, Journal of Ethnopharmacology 140(3): 458–68.

Valdés, R. and Tavengwa, R. (2012), “Intellectual Property Provisions in Regional Trade Agreements”, WTO Staff Working paper ERSD–2012–21.

van den Ham, R., Bero, L. and Laing, R. (2011), The World Medicines Situation 2011: Selection of Essential Medicines, Geneva, WHO.

Verbeure, B. et al. (2006), “Patent Pools and Diagnostic Testing”, Trends in Biotechnology 24(3): 115–20.

Von der Ropp, A. and Taubman, T. (2004), “Bioethics and Patent Law: The Case of Myriad”, WIPO Magazine 4: 8–9.

Wagner, A. et al. (2011), “Access to Care and Medicines, Burden of Health Care Expenditures, and Risk Protection: Results from the World Health Survey”, Health Policy 100(2–3): 151–58.

Waning, B., Diedrichsen, E. and Moon, S. (2010), “A Lifeline to Treatment: The Role of Indian Generic Manufacturers in Supplying Antiretroviral Medicines to Developing Countries”, Journal of the International AIDS Society 13: 35.

WHO (2000a), The World Health Report 2000: Health Systems – Improving Performance, Geneva, WHO.

WHO (2000b), General Guidelines on Methodologies for Research and Evaluation of Traditional Medicine, Geneva, WHO.

WHO (2001a), Macroeconomics and Health: Investing in Health for Economic Development, Geneva, WHO.

WHO (2001b), Legal Status of Traditional Medicine and Complementary/Alternative Medicine: A Worldwide Review, Geneva, WHO.

WHO (2001c), “Drug Procurement: The Principles for Getting It Right”, Essential Drugs Monitor 30, Geneva, WHO.

WHO (2001d), How to Develop and Implement a National Drug Policy, Geneva, WHO.

WHO (2002a), “The Selection and Use of Essential Medicines: Report of the WHO Expert Committee,” WHO Technical Report Series 914.

WHO (2002b), WHO Traditional Medicine Strategy 2002–2005, Geneva, WHO.

WHO (2003a), Medical Device Regulations: Global Overview and Guiding Principles, Geneva, WHO.

WHO (2003b), “How to Develop and Implement a National Drug Policy”, WHO Policy Perspectives on Medicines 6.

WHO (2004a), WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems, Geneva, WHO.

WHO (2004b), Priority Medicines for Europe and the World, Geneva, WHO.

WHO (2004c), “Equitable Access to Essential Medicines: A Framework for Collective Action”, WHO Policy Perspectives on Medicines 8.

WHO (2005a), Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies, Health Economics and Drugs TCM Series No. 18.

WHO (2005b), National Policy on Traditional Medicine and Regulation of Herbal Medicines: Report of a WHO Global Survey, Geneva, WHO.

WHO (2006a), Fortieth Report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series 937.

 

WHO (2006b), Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property Rights, Innovation and Public Health, Geneva, WHO.

WHO (2007), Everybody’s Business: Strengthening Health Systems to Improve Health Outcomes – WHO’s Framework for Action, Geneva, WHO.

WHO (2008), The Global Burden of Disease: 2004 Update, Geneva, WHO

WHO (2009), Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks, Geneva, WHO.

WHO (2010a), Medical Devices: Managing the Mismatch. Report of the Priority Medical Devices Project, Geneva, WHO.

WHO (2010b), Global Status Report on Noncommunicable Diseases 2010, Geneva, WHO.

WHO (2010c), Assessment of Medicines Regulatory Systems in Sub-Saharan African Countries: An Overview of Findings from 26 Assessment Reports, Geneva, WHO.

WHO (2010d), “World Health Organization Good Governance for Medicines Programme: An Innovative Approach to Prevent Corruption in the Pharmaceutical Sector”, World Health Report (2010) Background Paper 25

WHO (2010e), “New Progress and Guidance on HIV Treatment”, WHO Fact Sheet.

WHO (2010f), Working to Overcome the Global Impact of Neglected Tropical Diseases: First WHO Report on Neglected Tropical Diseases, Geneva, WHO.

WHO (2010g), Research and Development – Coordination and Financing: Report of the Expert Working Group, Geneva, WHO.

WHO (2010h), The World Health Report: Health Systems Financing – The Path to Universal Coverage, Geneva, WHO.

WHO (2011a), World Health Statistics, Geneva, WHO.

WHO (2011b), Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa, Geneva, WHO

WHO (2011c), Increasing Access to Vaccines Through Technology Transfer and Local Production, Geneva, WHO.

WHO (2011d), WHO Model List of Essential Medicines, 17th list, Geneva, WHO.

WHO (2011e), Pharmaceutical Production and Related Technology Transfer, Geneva, WHO

WHO (2011f), WHO Model List of Essential Medicines for Children, 3rd list, Geneva, WHO.

WHO (2011g), Local Production for Access to Medical Products: Developing a Framework to Improve Public Health, Geneva, WHO.

WHO (2011h), WHO’s Role in the Prevention and Control of Medical Products of Compromised Quality, Safety and Efficacy such as Substandard/Spurious/Falsely-Labelled/Falsified/Counterfeit Medical Products, Geneva, WHO (A/SSFFC/WG/3 Rev.1). Available at: http://apps.who.int/gb/ssffc/e/ssffc_wg1.html.

WHO (2012a), Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination, Geneva, WHO.

WHO (2012b), The Strategic Use of Antiretrovirals to Help End the HIV Epidemic, Geneva, WHO.

WHO (2012c), World Health Statistics 2012, Geneva, WHO.

WHO/HAI (2008), Measuring Medicine Prices, Availability, Affordability and Price Components, Geneva, WHO, and Amsterdam, HAI.

WHO/UNAIDS (2002), Accelerating Access Initiative: Widening Access to Care and Support for People Living with HIV/AIDS, Geneva, WHO/UNAIDS.

WHO/UNAIDS/UNICEF (2011), Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access: Progress Report 2011, Geneva, WHO.

WHO/UNICEF (2006), Essential Medicines for Children Expert Consultation Report of the Joint WHO-UNICEF Consultation on Essential Medicines for Children, Geneva, WHO.

WHO/UNICEF/World Bank (2009), State of the World’s Vaccines and Immunization, Geneva, WHO.

WHO/WTO (2002), WTO Agreements and Public Health: A Joint Study by the WTO and the WTO Secretariat, Geneva, WTO.

Widdus, R. and White, K. (2004), Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential Role of Public–Private Partnerships, Geneva, WHO.

WIPO (2001), Intellectual Property Needs and Expectations of Traditional Knowledge Holders: WIPO Report on Fact-Finding Missions on Intellectual Property and Traditional Knowledge (1998–1999), Geneva, WIPO.

WIPO (2008), SCP/12/3 Rev.2, Annex III Comments on the Report on the International Patent Systems Received from Members and Observers of the SCP, Geneva, WIPO.

WIPO (2009), The Economics of Intellectual Property, Geneva, WIPO.

WIPO (2010), Guide to Technology Databases, Geneva, WIPO.

WIPO (2011a), World Intellectual Property Report, Geneva, WIPO.

WIPO (2011b), WIPO Survey on Patenting Strategies in 2009 and 2010, Geneva, WIPO.

WIPO (2011c), WIPO Patent Search Report on Pandemic Influenza Preparedness (PIP)-Related Patents and Patent Applications, Geneva, WIPO.

WIPO (2012), PCT Yearly Review 2012: The International Patent System, Geneva, WIPO.

World Bank (2005), A Guide to Competitive Vouchers in Health, Washington, DC, World Bank.

World Bank (2009), “Europe and Central Asia Health Insurance and Competition”, World Bank Report No. 44316-ECA.

World Bank (2011), “Governance in the Health Sector: A Strategy for Measuring Determinants and Performance”, Policy Research Working Paper 5655.

WTO (2001), Workshop on Differential Pricing and Financing of Essential Drugs: Background Note Prepared by Jayashree Watal, Consultant to the WTO Secretariat, Geneva, WTO.

WTO (2009), “Services Liberalization from a WTO/GATS Perspectives: In Search of Volunteers”, WTO Staff Working Paper ERSD–2009–05.

WTO (2010), Annual Review of the Decision on the Implementation of Paragraph 6 of the Doha Declaration of the TRIPS Agreement and Public Health, Geneva, WTO

WTO (2011), World Trade Report 2011, Geneva, WTO. Yadav, P. (2010), “Differential Pricing for Pharmaceuticals: Review of Current Knowledge, New Findings and Ideas for Action”, A study

conducted for the UK Department for International Development (DFID). Yamane, H. (2011), Interpreting TRIPS: Globalisation of Intellectual

Property Rights and Access to Medicines, Oxford and Portland, Oregon, Hart Publishing.